このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Arcadia Biosciences マネジメント

マネジメント基準チェック /34

現在、CEO に関する十分な情報がありません。

主要情報

Stan Jacot

最高経営責任者

US$525.2k

報酬総額

CEO給与比率	66.6%
CEO在任期間	2.3yrs
CEOの所有権	0.4%
経営陣の平均在職期間	データなし
取締役会の平均在任期間	6.1yrs

経営陣の近況

Recent updates

We Think Shareholders Should Be Aware Of Some Factors Beyond Arcadia Biosciences' (NASDAQ:RKDA) Profit

Nov 22

The Future Looks Bright For Arcadia Biosciences

Dec 01

Arcadia Biosciences EPS misses by $0.06

Nov 12

CEO報酬分析

Arcadia Biosciences の収益と比較して、Stan Jacot の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-US$6m
Dec 31 2023	US$525k	US$350k	-US$13m
Sep 30 2023	n/a	n/a	-US$14m
Jun 30 2023	n/a	n/a	-US$14m
Mar 31 2023	n/a	n/a	-US$15m
Dec 31 2022	US$777k	US$307k	-US$11m

報酬と市場: Stanの総報酬 ($USD 525.18K ) は、 US市場 ($USD 673.68K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Stanの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Stan Jacot (53 yo)

2.3yrs

在職期間

US$525,177

報酬

Mr. Stanley E. Jacot, Jr., also known as Stan, is Chief Executive Officer of Arcadia Biosciences, Inc. since February 02, 2022 and serves as its President since February 2022. He serves as Director at Arca...

取締役

名称	ポジション	在職期間	報酬	所有権
Stanley Jacot	President	2yrs	US$525.18k	0.37% $ 15.3k
Gregory Waller	Independent Director	7yrs	US$68.32k	0% $ 0
Lilian Murray	Independent Director	6yrs	US$68.32k	0.016% $ 652.6
Albert Bolles	Independent Director	6.1yrs	US$50.32k	0% $ 0
Kevin Comcowich	Independent Chair of the Board	7.7yrs	US$99.09k	0.037% $ 1.5k
Amy Yoder	Independent Director	6.8yrs	US$64.82k	0% $ 0
Deborah Carosella	Independent Director	3.3yrs	US$57.48k	0% $ 0

6.1yrs

平均在職期間

65yo

平均年齢

経験豊富なボード: RKDAの取締役会は経験豊富であると考えられます ( 6.1年の平均在任期間)。

Arcadia Biosciences マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Arcadia Biosciences, Inc., Annual General Meeting, Jun 25, 2024

Insufficient new directors

Arcadia Biosciences, Inc. Announces the Resignation of Laura Pitlik as Chief Marketing Officer

Arcadia Biosciences, Inc. Announces CFO Changes

Arcadia Biosciences, Inc., Annual General Meeting, Jun 01, 2022

Arcadia Biosciences, Inc. Announces Executive Changes

Recent updates

Consensus revenue estimates decrease by 17%, EPS upgraded

Arcadia Biosciences, Inc., Annual General Meeting, Jun 25, 2024

First quarter 2024 earnings released: US$1.78 loss per share (vs US$10.86 loss in 1Q 2023)

First quarter 2024 earnings released: US$1.78 loss per share (vs US$10.86 loss in 1Q 2023)

Arcadia Biosciences, Inc. to Report Q1, 2024 Results on May 09, 2024

Consensus revenue estimates fall by 27%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Arcadia Biosciences, Inc. to Report Q4, 2023 Results on Mar 28, 2024

Insufficient new directors

Arcadia Biosciences, Inc. (Rkda) Expands Goodwheat™ Mac & Cheese with Nationwide Availability

Arcadia Biosciences, Inc. Announces the Resignation of Laura Pitlik as Chief Marketing Officer

Consensus EPS estimates fall by 31%

Consensus EPS estimates upgraded to US$7.44 loss

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Arcadia Biosciences, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Consensus revenue estimates increase by 13%, EPS downgraded

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Arcadia Biosciences, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Arcadia Biosciences, Inc. Launches Goodwheat into the Breakfast Category with New Better-For-You Pancake & Waffle Mixes and Single-Serve Quikcakes

First quarter 2023 earnings released: US$10.86 loss per share (vs US$8.09 loss in 1Q 2022)

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

We're Hopeful That Arcadia Biosciences (NASDAQ:RKDA) Will Use Its Cash Wisely

Arcadia Biosciences, Inc. Announces CFO Changes

Consensus forecasts updated

Price target decreased to US$2.50

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Arcadia Biosciences, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Arcadia Biosciences, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Arcadia Biosciences Receives Non-Compliance Letter from Nasdaq

Arcadia Biosciences to raise $5M in securities offering

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Arcadia Biosciences, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Arcadia Biosciences, Inc. to Report Q1, 2022 Results on May 12, 2022

Price target decreased to US$3.75

Arcadia Biosciences, Inc., Annual General Meeting, Jun 01, 2022

Consensus revenue estimates fall by 45%

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Arcadia Biosciences, Inc. Announces Executive Changes

Investor sentiment improved over the past week

Price target decreased to US$5.25

Chief Growth Officer Chris Cuvelier has left the company

Arcadia Biosciences: Market Still Unconvinced Of Its Health Offerings

We Think Shareholders Should Be Aware Of Some Factors Beyond Arcadia Biosciences' (NASDAQ:RKDA) Profit

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: US$0.098 loss per share (vs US$0.60 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.24 loss per share (vs US$1.04 loss in 2Q 2020)

Consensus EPS estimates increase to -US$0.81

Price target increased to US$5.75

Consensus revenue estimates increase to US$8.87m

Arcadia Biosciences, Inc. (NasdaqCM:RKDA) acquired Assets of Lief Holdings, LLC and Live Zola, LLC. from Lief Holdings, LLC and Live Zola, LLC for $6.1 million.

Consensus forecasts updated

Full year 2020 earnings released: US$0.47 loss per share (vs US$4.53 loss in FY 2019)

Price target raised to US$7.53

Arcadia Biosciences, Inc. Expands GoodWheat™ Patent Portfolio

Arcadia Biosciences Welcomes Debbie Carosella to Board Of Directors

New 90-day high: US$3.58

Arcadia Biosciences, Inc. announced that it expects to receive $25.146633 million in funding

New 90-day high: US$3.45

Arcadia Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $7.672668 million.

Price target lowered to US$9.33

New 90-day low: US$2.53

Analysts update estimates

The Future Looks Bright For Arcadia Biosciences

Arcadia Biosciences, Inc. Signs Hemp Distribution Agreement with Tritium 3H, Inc

マネジメント基準チェック /34